The American Journal of Managed Care14 小时
Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...
News Medical on MSN2 天
Study uncovers molecular mechanisms behind insulin resistance in skeletal muscle
Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high ...
Daily12 小时
Deucravacitinib Shows Consistent Efficacy in Psoriasis Treatment: Study
Researchers have found in a new study that deucravacitinib effectively reduces Psoriasis Area and Severity Index (PASI) and ...
BioSpace2 天
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
ophthalmologytimes2 天
Shaping the future of retinal therapy
The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...
ascopubs.org4 天
Olanzapine for managing side effects from tyrosine-kinase inhibitors.
A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab ...
GlobalData on MSN15 小时
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...